Description
Get quick access to reliable drug, disease, and diagnostic information at the point of care. Epocrates is the #1 mobile drug reference among U.S. physicians. Trusted for accurate content and innovative offerings, 50% of U.S. physicians rely on Epocrates to help improve patient safety and increase practice efficiency.
You’ll need to verify your account with Epocrates to use this app. To create an account, please visit: www.epocrates.com/verify
★ ★ ★ ★ ★
What does Epocrates offer?
*FREE*
- Clinical information on thousands of prescription, generic, and OTC drugs
- In-depth formulary information
- Pill ID: identify pills by imprint code and physical characteristics
- InteractionCheck: check for adverse reactions between up to 30 drugs at a time
- Dozens of calculations, such as BMI and GFR
- Current medical news, research, and information
*PREMIUM*
- Evidence-based treatment info for hundreds of diseases and conditions
- Specific/empiric treatment guidelines for hundreds of infectious diseases.
- Lab prep, interpretation, and follow-up for hundreds of tests & panels
- Medical dictionary (over 100,000 medical terms)
- Over 20,000 ICD-9 and CPT® codes
Review app pricing, features, and more at: www.epocrates.com/iphone.
What's New in Version 4.3.1
- Fixed the issue causing duplicate and blank EssentialPoints activities
- Improved performance
iPhone Screenshots
Customer Reviews
Great for EMS!
I'm a firefighter paramedic and use this app frequently. Pill ID is flawless and the drug info is quick and easy to obtain.
Great resource at point of care
As a practicing family physician, I find this app useful in almost every patient encounter, from double-checking med interactions, to showing patients pictures of pills to find out what strength they are taking, to reviewing half-life information...
- Free
- Category: Medical
- Updated: May 29, 2012
- Version: 4.3.1
- Size: 12.6 MB
- Language: English
- Seller: Epocrates
- © Epocrates, Inc
Requirements: Compatible with iPhone, iPod touch, and iPad.Requires iOS 3.0 or later
